Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: A historical, prospective secondary analysis

H. Michael Arrighi, Jerome Barakos, Frederik Barkhof, Donatella Tampieri, Clifford R Jr. Jack, Denis Melançon, Kristen Morris, Nzeera Ketter, Enchi Liu, H. Robert Brashear

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background Amyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's disease (AD) and have been reported with increased incidence in clinical trials of amyloid-lowering therapies under development for AD. Objective Our objective was to explore the relationship between the incidences of ARIA-H during treatment with placebo and different doses of bapineuzumab, a humanised monoclonal antibody directed against amyloid β. Methods Two neuroradiologists independently reviewed 2572 GRE/T2∗ MRI sequences from 262 participants in two phase two clinical trials of bapineuzumab and an open-label extension study. Readers were blinded to the participant's therapy, APOE ε4 genotype and medical history. Results Several risk factors for small ARIA-H

Original languageEnglish (US)
Pages (from-to)106-112
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume87
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Hemosiderin
Amyloid
Alzheimer Disease
Clinical Trials
Antibodies, Monoclonal, Humanized
Incidence
Dementia
bapineuzumab
Imaging
Alzheimer's Disease
Secondary Analysis
Therapeutics
Genotype
Placebos
Therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Surgery
  • Arts and Humanities (miscellaneous)

Cite this

Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab : A historical, prospective secondary analysis. / Arrighi, H. Michael; Barakos, Jerome; Barkhof, Frederik; Tampieri, Donatella; Jack, Clifford R Jr.; Melançon, Denis; Morris, Kristen; Ketter, Nzeera; Liu, Enchi; Brashear, H. Robert.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 87, No. 1, 01.01.2016, p. 106-112.

Research output: Contribution to journalArticle

Arrighi, H. Michael ; Barakos, Jerome ; Barkhof, Frederik ; Tampieri, Donatella ; Jack, Clifford R Jr. ; Melançon, Denis ; Morris, Kristen ; Ketter, Nzeera ; Liu, Enchi ; Brashear, H. Robert. / Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab : A historical, prospective secondary analysis. In: Journal of Neurology, Neurosurgery and Psychiatry. 2016 ; Vol. 87, No. 1. pp. 106-112.
@article{84097c17cdf64e56a01c27182aa5bc5c,
title = "Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: A historical, prospective secondary analysis",
abstract = "Background Amyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's disease (AD) and have been reported with increased incidence in clinical trials of amyloid-lowering therapies under development for AD. Objective Our objective was to explore the relationship between the incidences of ARIA-H during treatment with placebo and different doses of bapineuzumab, a humanised monoclonal antibody directed against amyloid β. Methods Two neuroradiologists independently reviewed 2572 GRE/T2∗ MRI sequences from 262 participants in two phase two clinical trials of bapineuzumab and an open-label extension study. Readers were blinded to the participant's therapy, APOE ε4 genotype and medical history. Results Several risk factors for small ARIA-H",
author = "Arrighi, {H. Michael} and Jerome Barakos and Frederik Barkhof and Donatella Tampieri and Jack, {Clifford R Jr.} and Denis Melan{\cc}on and Kristen Morris and Nzeera Ketter and Enchi Liu and Brashear, {H. Robert}",
year = "2016",
month = "1",
day = "1",
doi = "10.1136/jnnp-2014-309493",
language = "English (US)",
volume = "87",
pages = "106--112",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab

T2 - A historical, prospective secondary analysis

AU - Arrighi, H. Michael

AU - Barakos, Jerome

AU - Barkhof, Frederik

AU - Tampieri, Donatella

AU - Jack, Clifford R Jr.

AU - Melançon, Denis

AU - Morris, Kristen

AU - Ketter, Nzeera

AU - Liu, Enchi

AU - Brashear, H. Robert

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background Amyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's disease (AD) and have been reported with increased incidence in clinical trials of amyloid-lowering therapies under development for AD. Objective Our objective was to explore the relationship between the incidences of ARIA-H during treatment with placebo and different doses of bapineuzumab, a humanised monoclonal antibody directed against amyloid β. Methods Two neuroradiologists independently reviewed 2572 GRE/T2∗ MRI sequences from 262 participants in two phase two clinical trials of bapineuzumab and an open-label extension study. Readers were blinded to the participant's therapy, APOE ε4 genotype and medical history. Results Several risk factors for small ARIA-H

AB - Background Amyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's disease (AD) and have been reported with increased incidence in clinical trials of amyloid-lowering therapies under development for AD. Objective Our objective was to explore the relationship between the incidences of ARIA-H during treatment with placebo and different doses of bapineuzumab, a humanised monoclonal antibody directed against amyloid β. Methods Two neuroradiologists independently reviewed 2572 GRE/T2∗ MRI sequences from 262 participants in two phase two clinical trials of bapineuzumab and an open-label extension study. Readers were blinded to the participant's therapy, APOE ε4 genotype and medical history. Results Several risk factors for small ARIA-H

UR - http://www.scopus.com/inward/record.url?scp=84956581698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956581698&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2014-309493

DO - 10.1136/jnnp-2014-309493

M3 - Article

C2 - 25669746

AN - SCOPUS:84956581698

VL - 87

SP - 106

EP - 112

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 1

ER -